AY 9944 is a specific cholesterol biosynthesis inhibitor. AY 9944 inhibits the 7-dehydro cholesterol Δ7-reductase (DHCR7) enzyme with an IC50 of 13 nM. AY 9944 causes hypocholesterolemia and accumulation of 7DHC. At high doses, AY 9944 inhibits also in cultured embryos sterol Δ7-Δ8 isomerase, which causes the accumulation of cholest-8-en-3β-ol.
性状
Solid
IC50 & Target[1][2]
IC50: 13 nM (DHCR7)
体外研究(In Vitro)
AY 9944 (1 μg/mL; 15 h) affects types of free sterol in keratinocytes.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay
Cell Line:
Human foreskin keratinocytes
Concentration:
1 μg/mL
Incubation Time:
15 hours
Result:
Inhibited the synthesis of cholesterol and desmosterol, but increased 7-dehydrocholesterol and zymosterol synthesis.
体内研究(In Vivo)
AY 9944 (7.5 mg/kg; i.h. every 6 days once from postnatal day 2 to postnatal day 20) reduces brain cholesterol until 400 days after stop treatment.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
Long–Evans hooded rats.
Dosage:
7.5 mg/kg
Administration:
Subcutaneous injection; 7.5 mg/kg every 6 days once; from postnatal day 2 to postnatal day 20
Result:
Reduced brain cholesterol and increased 7-dehydrocholesterol in all brain regions of rats till the treatment stopped for 400 days and showed a more severe effect on the change of sterols in plasma and liver of female rats.